Bupropion Sustained-Release 90 mg Combined with Naltrexone for Alcohol Use Disorder
The optimal formulation is bupropion sustained-release (SR) 90 mg combined with naltrexone 8 mg, titrated to a maintenance dose of 2 tablets twice daily (total daily dose: naltrexone 32 mg/bupropion 360 mg). This is the FDA-approved fixed-dose combination formulation that has been studied for addiction-related conditions 1, 2.
Dosing Algorithm
Titration Schedule
The evidence from obesity guidelines provides the clearest dosing framework for naltrexone-bupropion SR combinations 1:
- Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion SR) once daily in the morning
- Week 2: 1 tablet twice daily (morning and evening)
- Week 3: 2 tablets in the morning, 1 tablet in the evening
- Week 4 onward: 2 tablets twice daily (maintenance dose)
Take the second dose earlier in the day to minimize insomnia risk 1.
Dose Adjustments for Organ Impairment
- Moderate to severe renal impairment: Reduce total daily dose by half (1 tablet twice daily); avoid in end-stage renal disease 1
- Moderate to severe hepatic impairment: Maximum 1 tablet daily 1
Evidence Supporting This Combination for Alcohol Use Disorder
While the FDA-approved fixed-dose combination was developed for obesity, emerging research supports its efficacy for alcohol use disorder:
Preclinical Evidence
Multiple animal studies demonstrate that combining low-dose naltrexone with bupropion reduces alcohol consumption more effectively than either agent alone 3, 4, 5. Notably, doses ineffective individually become effective when combined, suggesting synergistic mechanisms 3.
Human Evidence
A preliminary open-label study in binge drinkers showed that naltrexone 50 mg/day plus bupropion-ER 300 mg/day reduced:
- Average drinks per binge episode from 7.8 to 6.4 drinks
- Percentage of binge drinking days from 19% to 5% per month 6
The combination was generally well-tolerated, with insomnia, headache, and nausea being the most common side effects 6.
Mechanism of Action
The synergy derives from complementary mechanisms 1:
- Bupropion activates anorexigenic POMC neurons in the hypothalamus but has weak standalone effects due to β-endorphin auto-inhibition
- Naltrexone blocks this β-endorphin-mediated auto-inhibition, enhancing bupropion's effects
- This dual mechanism modulates both hedonic reward pathways (relevant to alcohol) and hypothalamic appetite circuits
Critical Safety Considerations
Absolute Contraindications
- Seizure disorders or conditions lowering seizure threshold (stroke, brain metastases) 1, 7, 1
- Current or recent (within 14 days) MAO inhibitor use 1
- Uncontrolled hypertension 1
- Acute opioid withdrawal or current opioid therapy (naltrexone will precipitate withdrawal or block analgesic effects) 1
- End-stage renal disease 1
Important Warnings
- Monitor blood pressure: Modest increases in systolic/diastolic BP may occur, particularly in first 8 weeks 1
- Neuropsychiatric monitoring: Watch for depression, suicidal ideation, agitation, or hostility, especially in patients <24 years 1, 7
- Hold before procedures requiring opioids: Discontinue naltrexone-containing medications before surgeries or procedures where fentanyl or other opioids will be used 1
Clinical Pearls
Advantages for Alcohol Use Disorder Patients
- Comorbid depression: Bupropion at 300 mg daily (close to the 360 mg in this combination) is effective for major depression 1
- Comorbid smoking: The combination shows efficacy for smoking cessation 1
- Comorbid obesity: FDA-approved indication with demonstrated weight loss benefits 1
Tolerability Management
- Nausea: Most common side effect; may require slower titration or temporary dose reduction
- Insomnia: Take second dose earlier in the day, not late afternoon/evening 1
- Titration is critical: Weekly escalation minimizes adverse effects and improves adherence 1
Comparison to Standard AUD Pharmacotherapy
While naltrexone monotherapy (50 mg/day) is FDA-approved for AUD, recent meta-analyses show variable efficacy 8. The combination approach may offer advantages:
- Lower naltrexone dose (32 mg vs 50 mg) may reduce side effects
- Synergistic mechanism addresses multiple pathways
- Bupropion addresses comorbid depression/smoking common in AUD
However, direct head-to-head trials comparing naltrexone-bupropion combination to standard naltrexone monotherapy for AUD are lacking. The evidence base for this combination in AUD remains preliminary compared to established treatments like naltrexone or acamprosate monotherapy 9.
Monitoring and Duration
- Assess response at 12 weeks: If no meaningful reduction in drinking, consider alternative treatments
- Long-term treatment: Evidence supports chronic treatment for sustained benefit, similar to other addiction pharmacotherapies 1
- Combine with behavioral therapy: Pharmacotherapy should be paired with psychosocial interventions for optimal outcomes 10